Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: A phase II study

Clinical Lung Cancer

Volumn 11, Issue 1, 2010, Pages 30-35

  Katirtzoglou, Nikolaos ^a   Gkiozos, Ioannis ^a   Makrilia, Nektaria ^a   Tsaroucha, Emilia ^a   Rapti, Aggeliki ^a   Stratakos, Grigorios ^a   Fountzilas, Georgios ^b   Syrigos, Konstantinos N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Asbestos; Epithelioid; Expanded access program; Sarcomatoid

Indexed keywords

ASBESTOS; CARBOPLATIN; PEMETREXED;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; THROMBOCYTOPENIA;

EID: 77249101787     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.005     Document Type: Article

References (35)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644
2. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23:6881-6889
3. Kalmadi SR, Rankin C, Kraut MJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008; 60:259-263
4. Maziak DE, Gagliardi A, Haynes AE, et al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005; 48:157-169
5. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 2004; 45(suppl 1):103-119
6. Ellis P, Davies AM, Evans WK, et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006; 1:591-601.
7. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007; 62(suppl 2):ii1-ii9.
8. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis. Lung Cancer 2002; 38:111-121
9. Favaretto A. Overview on ongoing or planned clinical trials in Europe. Lung Cancer 2005; 49(suppl 1):117-121
10. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21:1556-1561
11. Thödtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999; 17:3009-3016 (Pubitemid 29470627)
12. Calvert AH, Hughes AN, Calvert PM, et al. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial. Lung Cancer 2000; 29(suppl 2):73-74
13. Obasaju CK, Ye Z, Wozniak AJ, et al. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 2007; 55:187-194
14. Santoro A, OBrien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3:756-763
15. Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta). The Oncologist 2004; 9:482-488
16. Lee CW, Murray N, Anderson H, et al. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 2009; 64:308-313
17. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24:1443-1448
18. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19:370-373 (Pubitemid 351201722)
19. Li L, Razak AR, Hughes A. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: A realistic treatment option? Lung Cancer 2009; 64:207-210
20. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17:25-30.
21. Nowak AK, Byrne MJ, Williamson R. A multicenter phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87:491-496
22. Pinto C, Marino A, De Pangher Manzini V, et al. Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant mesothelioma. A multicenter Italian Phase II Study (SITMP1). Lung Cancer 2006; 52:199-206.
23. Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma: An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 1991; 67:2984-2987
24. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993; 11:1559-1565
25. Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003; 21:349-354
26. Schutte W, Blankenburg T, Lauerwald K, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003; 4:294-297
27. Fennell DA, Steele JP, Shamash J, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005; 47:277-281
28. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 2007; 25(18 suppl):391s (abstract 7526).
29. Krug LM, Pass H, Rusch VW, et al. A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM). J Clin Oncol 2007; 25(18 suppl):399s (abstract 7561).
30. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108:1122-1128
31. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
32. Therasse P, Arbuck S, Eisenhauer E. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
33. Hazarika M, White Jr RM, Booth BP, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005; 11:982-992
34. Oxnard GR, Amato SG, Salgia A. Development of response criteria for mesothelioma based on mathematical model. J Clin Oncol 2005; 23(16 suppl):664s (abstract 7176).
35. Fennell D, Steele J, Sheaff M, et al. Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer 2005; 49(2 suppl):S220 (abstract P-397).